男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

USEUROPEAFRICAASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Biotechnology incubator opens doors in Boston

By HONG XIAO in New York | China Daily | Updated: 2017-05-23 08:20

Chinese investors have begun to shift target industries in the US to the high-tech sector and the trend just took a big step in Boston.

The city's first innovation center founded by a Chinese pharmaceutical enterprise - Qilu Boston Innovation Center - its grand opening on Friday.

After launching, "QBIC will be serving as an incubator for biotech startups, with the aim of helping biotechnology startups implement their ideas, to sooner transform their research results into medicine to meet clinical needs and improving Qilu's domestic product lines," said Larry Cai, head of business development in New England at Qilu.

Founded by Qilu Pharmaceutical, a Chinese drug company with more than $2 billion in annual sales, QBIC will be set up in a two-story building at 50 Soldiers Field Place that was acquired by Qilu last year for around $10 million.

Along with the incubator, Qilu's first branch company in Massachusetts - QLB Biotherapeutics Inc (QLB Bio) - also set up shop in the new facility on the same day.

With the remodeling, the 2,300-square-meter center with lab and office space becomes Qilu's biggest overseas research and development site.

Established in 1958 and headquartered in the city of Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China, with a value chain focusing on the development, manufacture and marketing of drugs and biologics.

After years of expansion, the company now has nine manufacturer sites, 13 domestic subsidiaries, 10 overseas subsidiaries and more than 9,000 staff worldwide. With sales revenue of approximately $2.1 billion, Qilu products are available in more than 70 countries worldwide.

"The opening of QBIC and the entering of QLB Bio is not only a milestone in the history of Qilu Pharmaceutical, it's a brand new start for the company," said Li Yan, general manager of Qilu.

Li said she believes that having access to affordable innovative drugs is everybody's basic right, rather than a few people's privilege.

"Over the past 30 years, Qilu has been committed to continuously providing high quality drugs to protect and promote public health," she said.

"Boston is the world's leading city in bioscience," Li said. Qilu choose to settle there because the company wants to interact with biotech elites, explore the unknown areas of bioscience and continuously research and develop innovative drugs to meet urgent clinical needs.

Cai said the company's total investment in Boston was about $40 million.

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 安康市| 五原县| 黑龙江省| 阆中市| 遂宁市| 梅州市| 定结县| 铁岭市| 张北县| 石台县| 镇原县| 吴川市| 无为县| 崇左市| 昔阳县| 和平县| 广饶县| 苍溪县| 德格县| 两当县| 芦溪县| 米脂县| 五寨县| 靖宇县| 屯昌县| 辛集市| 明光市| 上林县| 天峨县| 岗巴县| 平顶山市| 嘉黎县| 金山区| 鲁山县| 昭觉县| 阜阳市| 类乌齐县| 墨竹工卡县| 奉贤区| 房产| 高密市|